Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease - Wikidata - awgldk - TriplyDB

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

http://www.wikidata.org/entity/Q33646625

about

Atherosclerosis and infection: is the jury still not in?Antibiotics for secondary prevention of coronary heart disease Peripheral artery disease: epidemiology and global perspectives.Excess sudden cardiac deaths after short-term clarithromycin administration in the CLARICOR trial: why is this so, and why are statins protective?Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.In silico analyses of metagenomes from human atherosclerotic plaque samples.Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis.Biotic acts of antibiotics Preventing cardiovascular complications of acute infection: a missed opportunity?Antibiotic-induced cardiac arrhythmias.Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) T Antibiotics for secondary prevention of coronary heart disease Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial Prognostic value of routinely available data in patients with stable coronary heart disease. A 10-year follow-up of patients sampled at random times during their disease course Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial

P2860

Q22241306-E952F5F8-251E-483C-ACDD-A7AD46B4B043 Q24201388-2F7C784A-20C6-4DCA-8CA8-D0E28706F62E Q30241154-662CDF17-D488-49EF-B29D-CADED60124C2 Q34174166-3B2DFB1F-979C-4B5E-B76B-B55DC59DF60C Q34389792-FF76A543-E5B6-43C0-AF9D-24E143228E47 Q35763057-8D6E3EAA-0402-47E5-B8B0-83CE89F3BCBE Q36342810-684AFE16-39BB-465E-B110-56E1DC485F0B Q37101851-F3F2DFCE-C5F7-4F0F-97AE-6EBD5E0CDCEE Q37693966-7F86EC7C-5E26-4CC1-9495-9B6C270BD9B4 Q38178757-1C095B83-48DD-4F09-992C-87470D827989 Q41327770-E66875F3-0DAB-417E-ADCD-098AD2614063 Q46738236-2DDEEC51-C151-4184-BB6F-FD60B1878221 Q55445795-76B5752E-C66B-4075-AEFC-9AA74383FA2D Q57389403-A0CA661C-4BBA-4F17-BA0A-3022A2A88C7C Q57389466-B229631B-E08B-482B-B226-AB515BE1C036 Q57389527-C7CD7982-F036-4B73-9437-38FCAC0BB884 Q58040795-692CF05E-559D-42AC-BA62-D9F87C61623D Q58040909-BD836D1C-1693-40F4-82D1-2C1D1EA718F5

P2860

Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease

http://www.wikidata.org/entity/Q33646625

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@ast

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@en

type

label

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@ast

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@en

prefLabel

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@ast

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@en

P1433

Q33646625-C78D48C0-D7C5-42B9-8CA2-CE44A6EB7AE6

P1476

Q33646625-812CD406-FEEA-4B08-80F1-A37B0285333D

P2093

Q33646625-1AD07A29-53ED-4B24-A8FE-20FA0458A398

Q33646625-2E2CDF08-05E4-421E-AFDA-1FAA33203656

Q33646625-3F05E8E7-BC8A-4BA6-8BD8-BF692219076C

Q33646625-432CBD03-98A2-4AF1-A7DD-B7D6335AE83C

Q33646625-53315E44-2E66-41FF-85D9-4C8668F66A4C

Q33646625-57BB5729-A86D-4015-8B5F-C64DA65C28C6

Q33646625-5EE200BA-7E3F-4D87-81F8-9F0ED1D695C8

Q33646625-5FCCCC34-9C0A-4D49-9410-DE2A75E583A0

Q33646625-7965CC0B-0FD9-48A0-9EC4-4BAB05111FFD

Q33646625-B954B683-4323-4860-A40E-F2F37F039189

P2860

Q33646625-0A8DFA48-BC28-4515-88B0-502B126792C9

Q33646625-11860F5F-53BF-4A04-92D2-52FDA158633B

Q33646625-144F5838-D1E2-4543-939F-849639A270EF

Q33646625-1A2B60DF-BD68-42FB-B009-9999273E668B

Q33646625-1C87E317-C65B-4D15-BDAA-EFD01F8398D5

Q33646625-25199F16-807D-42AF-987F-A0457BF28257

Q33646625-378188B3-44F6-48F9-B401-E95F12CE28F1

Q33646625-483AAAE7-66C4-4735-A7F2-E55EFB9246CD

Q33646625-4B58308D-C101-404C-ABA4-0A69BA7799DF

Q33646625-52FA515A-A879-4B56-A1D7-5CF705B99F76

P304

Q33646625-C07ECADD-ACC7-4E96-AD27-C97821CC507A

P31

Q33646625-7540433F-1612-44B2-B7A4-345BB6E0C4E1

P356

Q33646625-5C53F54E-FC67-4228-A910-ABE3A66FC913

P407

Q33646625-05365990-7AD2-4E81-81CA-C87656EE310B

P433

Q33646625-4510B678-6D67-4519-B451-A011D5BB85A9

P478

Q33646625-98FA2F15-7E61-45B6-8869-2D52403B160E

P50

Q33646625-26FF514E-BAAD-46E4-B692-BC1038FCE360

Q33646625-38EAA6B7-3BC6-450E-B768-C87F7963F788

P577

Q33646625-19465789-65FF-45C1-82EB-AEA32282A179

P5875

Q33646625-B9A992E1-ECA8-4E4B-98A6-56D811DAFF94

P698

Q33646625-55A66D11-0BEF-4E47-B852-318BCE9FA582

P932

Q33646625-BD16112D-53DF-4472-8E0A-C5598FBDCD01

P356

P1433

P1476

Clarithromycin for 2 weeks for ...... ics for coronary heart disease

@en

P2093

Bodil Als-Nielsen

http://www.w3.org/2001/XMLSchema#string

CLARICOR Trial Group

http://www.w3.org/2001/XMLSchema#string

Christian M Jespersen

http://www.w3.org/2001/XMLSchema#string

Erik Kjøller

http://www.w3.org/2001/XMLSchema#string

Gorm Boje Jensen

http://www.w3.org/2001/XMLSchema#string

Hans Jørn Kolmos

http://www.w3.org/2001/XMLSchema#string

Henrik Nielsen

http://www.w3.org/2001/XMLSchema#string

Inga Lind

http://www.w3.org/2001/XMLSchema#string

Jens Kastrup

http://www.w3.org/2001/XMLSchema#string

Jørgen Fischer Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins

Quantifying heterogeneity in a meta-analysis

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

Contradicted and initially stronger effects in highly cited clinical research

Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials.

P304

280-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000128994

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Gorm Boje Jensen

Christian Gluud

P577

2008-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5400414

http://www.w3.org/2001/XMLSchema#string

P698

18451646

http://www.w3.org/2001/XMLSchema#string

P932

2820332

http://www.w3.org/2001/XMLSchema#string